Alcon Inc. - Registered Shares
ALC
Market Cap$41.13B
Close$
Earnings Call Q5 2023
February 28, 2024 - AI Summary
Alcon reported strong fourth quarter sales of $2.3 billion, up 10% year-over-year, driven by growth in both the Surgical and Vision Care franchises.
The company expects net sales for 2024 to be between $9.9 billion and $10.1 billion, representing constant currency growth of 6% to 8%. This is underpinned by a robust product portfolio and anticipated market growth.
Alcon plans to launch UNITY VCS, its next-generation Phacovit device, which is expected to drive upgrades and capture market share. FDA authorization is expected in the coming months, with international markets following in early 2025.
Exclusive for Stockcircle Pro members
Sign up
$12.59
84.1% downside
Current Fair Value
84.1% downsideOvervalued by 84.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $41.13 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.21 (0.26%) |
| Earnings per Share | $1.96 |
| Beta | 0.96 |
| Outstanding Shares | 499,700,000 |
| Avg 30 Day Volume | 870,159 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 42.23 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Alcon, Inc.
20,000 employees
CEO: David J. Endicott Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...